ArticleJournal of controlled release : official journal of the Controlled Release Society2017
Albumin-coated nanocrystals for carrier-free delivery of paclitaxel.
Article in Journal of controlled release : official journal of the Controlled Release Society, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 106 citations in OpenAlex.
- Engineered Extracellular Vesicles for Targeted Paclitaxel Delivery in Cancer Therapy: Advances, Challenges, and Prospects.Cellular and molecular bioengineering · 2025Review
- Evaluation of Nano-Niclosamide in KillingPharmaceutics · 2025Article
- Carrier-free nanoparticles-new strategy of improving druggability of natural products.Journal of nanobiotechnology · 2025Review
- Advances in Pure Drug Self-Assembled Nanosystems: A Novel Strategy for Combined Cancer Therapy.Pharmaceutics · 2025Review
- Nanocrystalline Drug Delivery Systems for Natural Compounds: Progress, Challenges and Future Opportunities.International journal of nanomedicine · 2025Review
- Nanocrystals and nanosuspensions: an exploration from classic formulations to advanced drug delivery systems.Drug delivery and translational research · 2024Review
- Formulation and evaluation of cetuximab functionalized phospholipid modified nanocrystals of paclitaxel for non-small cell lung cancer therapy.Scientific reports · 2024Article
- Review
- Spatiotemporal transformable nano-assembly for on-demand drug delivery to enhance anti-tumor immunotherapy.Asian journal of pharmaceutical sciences · 2024Article
- Systemic Delivery of Paclitaxel by Find-Me Nanoparticles Activates Antitumor Immunity and Eliminates Tumors.ACS nano · 2024Article
- Recent Advancements of Nanomedicine in Breast Cancer Surgery.International journal of nanomedicine · 2024Review
- GP60 and SPARC as albumin receptors: key targeted sites for the delivery of antitumor drugs.Frontiers in pharmacology · 2024Review
- Protein corona: Friend or foe? Co-opting serum proteins for nanoparticle delivery.Advanced drug delivery reviews · 2023Review
- Simple Multifunctional PTX@Ce6 Nanomedicine for Eradicating Tumor in the Combination of Photodynamic Therapy and Metronomic Chemotherapy.ACS omega · 2022Article
- Size optimization of carfilzomib nanocrystals for systemic delivery to solid tumors.Journal of controlled release : official journal of the Controlled Release Society · 2022Article
- Recrystallization of Adenosine for Localized Drug Delivery.Molecular pharmaceutics · 2022Article
- Article
- Hydroxypropyl Beta Cyclodextrin as a Potential Surface Modifier for Paclitaxel Nanocrystals.AAPS PharmSciTech · 2022Article
- A single local delivery of paclitaxel and nucleic acids via an immunoactive polymer eliminates tumors and induces antitumor immunity.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- Nanoparticle personalized biomolecular corona: implications of pre-existing conditions for immunomodulation and cancer.Biomaterials science · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Nanoparticles are used to deliver anticancer drugs to solid tumors. However, clinical development of nanoparticles is challenging because of their limitations in physicochemical properties, such as low drug loading efficiency and poor circulation stability. Low drug loading not only causes technical difficulty in administration but also increases the amount of co-delivered carrier materials, imposing biological burdens to patients. Poor circulation stability causes loss of pharmacokinetics benefits of nanoparticles. To overcome these challenges, we developed an albumin-coated nanocrystal (NC) formulation of paclitaxel (PTX) with 90% drug loading and high serum stability. The NC was produced by inducing crystallization of PTX in aqueous medium, coating the surface with albumin, and removing extra non-drug ingredients. Among three types of NC produced with different crystallization conditions, NC crystallized in the medium containing Pluronic F-127 then coated with albumin ("Cim-F-alb") had the smallest size and the most native albumin, thus showing the most favorable cell interaction profiles (low uptake by J774A.1 macrophages and high uptake by SPARC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.